The stock of Immatics N.V (IMTX) has seen a -14.00% decrease in the past week, with a -25.04% drop in the past month, and a -25.64% decrease in the past quarter. The volatility ratio for the week is 6.17%, and the volatility levels for the past 30 days are at 4.44% for IMTX. The simple moving average for the last 20 days is -17.36% for IMTX stock, with a simple moving average of -18.99% for the last 200 days.
Is It Worth Investing in Immatics N.V (NASDAQ: IMTX) Right Now?
Company’s 36-month beta value is 0.76.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for IMTX is 72.03M, and currently, short sellers hold a 13.21% ratio of that floaft. The average trading volume of IMTX on October 14, 2024 was 350.23K shares.
IMTX) stock’s latest price update
The stock of Immatics N.V (NASDAQ: IMTX) has decreased by -0.05 when compared to last closing price of 9.35. Despite this, the company has experienced a -14.00% fall in its stock price over the last five trading sessions. seekingalpha.com reported 2024-10-11 that Immatics is an early-stage biotech focused on cell-based immunotherapies for solid cancers. Their ACTEngine pipeline shows promise, particularly IMA203/IMA203CD8 targeting the PRAME antigen. Valuation estimates suggest a potential stock price of ~$19.26 based on conservative revenue assumptions.
Analysts’ Opinion of IMTX
Many brokerage firms have already submitted their reports for IMTX stocks, with Piper Sandler repeating the rating for IMTX by listing it as a “Overweight.” The predicted price for IMTX in the upcoming period, according to Piper Sandler is $19 based on the research report published on October 07, 2024 of the current year 2024.
Mizuho gave a rating of “Buy” to IMTX, setting the target price at $12 in the report published on March 31st of the previous year.
IMTX Trading at -18.25% from the 50-Day Moving Average
After a stumble in the market that brought IMTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.17% of loss for the given period.
Volatility was left at 4.44%, however, over the last 30 days, the volatility rate increased by 6.17%, as shares sank -26.34% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.91% lower at present.
During the last 5 trading sessions, IMTX fell by -14.00%, which changed the moving average for the period of 200-days by -10.96% in comparison to the 20-day moving average, which settled at $11.30. In addition, Immatics N.V saw -11.30% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for IMTX
Current profitability levels for the company are sitting at:
- -1.42 for the present operating margin
- -0.35 for the gross margin
The net margin for Immatics N.V stands at -1.04. The total capital return value is set at -0.21. Equity return is now at value -24.37, with -14.23 for asset returns.
Based on Immatics N.V (IMTX), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -0.48. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is -119.28.
Currently, EBITDA for the company is -80.65 million with net debt to EBITDA at 1.48. When we switch over and look at the enterprise to sales, we see a ratio of 10.67. The receivables turnover for the company is 19.67for trailing twelve months and the total asset turnover is 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.74.
Conclusion
In a nutshell, Immatics N.V (IMTX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
